Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Enoxaparin for VTE prevention in elderly hospitalized patients
NCT02379806Phase 3Completed
- Sponsor
- Centre Hospitalier Universitaire de Brest
- Start
- Sep 2015
- Primary completion
- Dec 2020
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial in venous thromboembolism (VTE) comparing Active enoxaparin 40 mg with Placebo (2 arms). Primary endpoint: Symptomatic confirmed deep venous thrombosis (DVT), symptomatic confirmed pulmonary embolism (PE), or fatal PE at Day 30. Started Sep 2015; status: completed.
02
Drugs
enoxaparin
03
Conditions
venous thromboembolism (VTE)
Beyond the preview
Go deeper on NCT02379806.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02379806.